Suppr超能文献

家族性淀粉样多神经病(葡萄牙V30M型)肝移植的长期定量评估

Long-term quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M).

作者信息

de Carvalho Mamede, Conceição Isabel, Bentes Carla, Luís M L Sales

机构信息

Laboratory of Electromyography and Evoked Potentials of Centro de Estudos Egas Moniz, Faculty of Medicine, Lisbon, Portugal.

出版信息

Amyloid. 2002 Jun;9(2):126-33.

Abstract

Familial amyloid polyneuropathy (FAP) is associated with massive endoneurial and extracellular deposition of amyloid, which isformed from a mutated transthyretin (TTR) protein. Ninety percent of TTR protein is produced in liver. Liver transplantation (LT) is the only treatment that can halt FAP clinical progression. We studied 35 LT patients. The mean age of the first symptoms was 36.6 years (ranging from 27 to 56), 19 were males, and 16 females, they underwent LT after a mean time of 5 years of symptomatic disease. Fifteen patients followed for more than 24 months after LT had periodic evaluations with clinical and neurophysiological scores (CS and NS). Ten were first evaluated before LT (mean follow-up time of 44 months after LT), and 5 were evaluated only after LT (or a mean time of 41 months). Five patients were followed periodically before LT (mean time of 44 months) to study the natural course of this condition. The mortality rate was of 14% in the first 6 months and was related to known complications of the surgery. No deaths occurred in the period 6 months to 1 year after LT. Five patients (14%) died 1-2 years after LT, 4 of whom were transplanted in advance stages. In the survival group, CS tended to stabilize shortly after LT and to remain invariable later on. The NSprogressed in the first year following LT, and subsequently it did not increase significantly. LT changed the natural course of FAP-I.

摘要

家族性淀粉样多神经病(FAP)与大量淀粉样蛋白在内神经和细胞外的沉积有关,这些淀粉样蛋白由突变的转甲状腺素蛋白(TTR)形成。90%的TTR蛋白在肝脏中产生。肝移植(LT)是唯一能够阻止FAP临床进展的治疗方法。我们研究了35例肝移植患者。首发症状的平均年龄为36.6岁(范围为27至56岁),男性19例,女性16例,他们在出现症状性疾病平均5年后接受了肝移植。15例患者在肝移植后随访超过24个月,定期进行临床和神经生理学评分(CS和NS)评估。10例在肝移植前首次评估(肝移植后平均随访时间为44个月),5例仅在肝移植后评估(或平均时间为41个月)。5例患者在肝移植前定期随访(平均时间为44个月)以研究该病的自然病程。最初6个月的死亡率为14%,与已知的手术并发症有关。肝移植后6个月至1年期间无死亡病例。5例患者(14%)在肝移植后1 - 2年死亡,其中4例在疾病晚期接受移植。在存活组中,CS在肝移植后不久趋于稳定,随后保持不变。NS在肝移植后的第一年有所进展,随后没有显著增加。肝移植改变了FAP - I的自然病程。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验